Eli Lilly (LLY) Total Debt (2009 - 2026)
Eli Lilly posted quarterly Total Debt of $43.4 billion for Q1 2026, up 12.6% year-on-year from $38.5 billion in Q1 2025, and up 2.04% on a QoQ basis from $42.5 billion in Q4 2025.
Eli Lilly (LLY) has 18 years of Total Debt data on file, last reported at $43.4 billion in Q1 2026.
- For the quarter ending Q1 2026, Total Debt rose 12.6% year-over-year to $43.4 billion; the trailing twelve-month figure through Mar 2026 stood at $43.4 billion (up 12.6% YoY), and the FY2025 full-year result was $42.5 billion, up 26.33% from the prior year.
- Total Debt for Q1 2026 stood at $43.4 billion, up from $42.5 billion in the prior quarter.
- Across five years, Total Debt topped out at $43.4 billion in Q1 2026 and bottomed at $15.9 billion in Q3 2022.
- The 5-year median for Total Debt is $26.2 billion (2024), against an average of $28.0 billion.
- The widest annual swing landed in 2022, when Total Debt slipped 7.01%; it then surged 55.34% in 2023.
- A 5-year view of Total Debt shows it stood at $16.2 billion in 2022, then soared by 55.34% to $25.2 billion in 2023, then jumped by 33.37% to $33.6 billion in 2024, then climbed by 26.33% to $42.5 billion in 2025, then advanced by 2.04% to $43.4 billion in 2026.
- The last three Total Debt figures came in at $43.4 billion (Q1 2026), $42.5 billion (Q4 2025), and $42.5 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 43.37 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 54.99 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 64.53 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 49.12 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 57.32 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 22.17 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 64.46 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 44.46 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 23.56 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43.37 Bn |
| Dec 31, 2025 | 42.50 Bn |
| Sep 30, 2025 | 42.51 Bn |
| Jun 30, 2025 | 39.90 Bn |
| Mar 31, 2025 | 38.52 Bn |
| Dec 31, 2024 | 33.64 Bn |
| Sep 30, 2024 | 31.12 Bn |
| Jun 30, 2024 | 28.89 Bn |
| Mar 31, 2024 | 26.21 Bn |
| Dec 31, 2023 | 25.23 Bn |
| Sep 30, 2023 | 20.17 Bn |
| Jun 30, 2023 | 18.82 Bn |
| Mar 31, 2023 | 18.88 Bn |
| Dec 31, 2022 | 16.24 Bn |
| Sep 30, 2022 | 15.89 Bn |
| Jun 30, 2022 | 16.81 Bn |
| Mar 31, 2022 | 16.51 Bn |
| Dec 31, 2021 | 16.88 Bn |
| Sep 30, 2021 | 17.09 Bn |
| Jun 30, 2021 | 16.52 Bn |
| Mar 31, 2021 | 16.20 Bn |
| Dec 31, 2020 | 16.60 Bn |
| Sep 30, 2020 | 16.92 Bn |
| Jun 30, 2020 | 16.33 Bn |
| Mar 31, 2020 | 17.23 Bn |
| Dec 31, 2019 | 15.32 Bn |
| Sep 30, 2019 | 15.23 Bn |
| Jun 30, 2019 | 15.79 Bn |
| Mar 31, 2019 | 15.97 Bn |
| Dec 31, 2018 | 10.30 Bn |
| Sep 30, 2018 | 12.68 Bn |
| Jun 30, 2018 | 12.22 Bn |
| Mar 31, 2018 | 11.70 Bn |
| Dec 31, 2017 | 13.65 Bn |
| Sep 30, 2017 | 13.46 Bn |
| Jun 30, 2017 | 12.31 Bn |
| Mar 31, 2017 | 10.25 Bn |
| Dec 31, 2016 | 10.31 Bn |
| Sep 30, 2016 | 9.35 Bn |
| Jun 30, 2016 | 9.33 Bn |
| Mar 31, 2016 | 8.13 Bn |
| Dec 31, 2015 | 7.98 Bn |
| Sep 30, 2015 | 8.08 Bn |
| Jun 30, 2015 | 8.00 Bn |
| Mar 31, 2015 | 8.22 Bn |
| Dec 31, 2014 | 8.02 Bn |
| Sep 30, 2014 | 5.61 Bn |
| Jun 30, 2014 | 5.31 Bn |
| Mar 31, 2014 | 5.26 Bn |
| Dec 31, 2013 | 5.21 Bn |
| Sep 30, 2013 | 5.28 Bn |
| Jun 30, 2013 | 5.31 Bn |
| Mar 31, 2013 | 5.46 Bn |
| Dec 31, 2012 | 5.53 Bn |
| Sep 30, 2012 | 5.52 Bn |
| Jun 30, 2012 | 5.51 Bn |
| Mar 31, 2012 | 5.41 Bn |
| Dec 31, 2011 | 6.99 Bn |
| Sep 30, 2011 | 7.08 Bn |
| Jun 30, 2011 | 6.73 Bn |
| Mar 31, 2011 | 6.67 Bn |
| Dec 31, 2010 | 6.93 Bn |
| Sep 30, 2010 | 7.14 Bn |
| Jun 30, 2010 | 6.89 Bn |
| Mar 31, 2010 | 6.68 Bn |
| Dec 31, 2009 | 6.66 Bn |
| Jun 30, 2009 | 7.72 Bn |